Literature DB >> 19501624

Suppression of xenogeneic graft-versus-host disease by treatment with immunoglobulin-like transcript 3-Fc.

George Vlad1, Michael B Stokes, Zhuoru Liu, Chih-Chao Chang, Hugo Sondermeijer, Elena R Vasilescu, Adriana I Colovai, Pasquale Berloco, Vivette D D'Agati, Lloyd Ratner, Raffaello Cortesini, Nicole Suciu-Foca.   

Abstract

Allogeneic hematopoietic cell transplantation represents an important therapy for certain malignant and nonmalignant diseases. However, graft-versus-host disease (GVHD) is a major cause of mortality and morbidity. The search for agents that can efficiently suppress GVHD has been going on for more than half a century. GVHD is particularly strong in xenogeneic donor-recipient combinations, given the unlimited number of potentially immunogenic antigens donor lymphocytes encounter in the host. Using a hu-nonobese diabetic/severe combined immunodeficiency (hu-NOD/SCID) gamma-null model of xenogeneic GVHD, we have demonstrated that treatment with recombinant immunoglobulin-like transcript 3-Fc protein induces the differentiation of CD8(+) T suppressor cells and blocks the cellular and humoral arm of the GVH reaction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19501624     DOI: 10.1016/j.humimm.2009.06.001

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  10 in total

1.  Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγnull mice display a T-effector memory phenotype.

Authors:  Niwa Ali; Barry Flutter; Robert Sanchez Rodriguez; Ehsan Sharif-Paghaleh; Linda D Barber; Giovanna Lombardi; Frank O Nestle
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

2.  Improved multilineage human hematopoietic reconstitution and function in NSGS mice.

Authors:  Mark Wunderlich; Fu-Sheng Chou; Christina Sexton; Pietro Presicce; Claire A Chougnet; Julio Aliberti; James C Mulloy
Journal:  PLoS One       Date:  2018-12-12       Impact factor: 3.240

Review 3.  Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer.

Authors:  Mi Deng; Heyu Chen; Xiaoye Liu; Ryan Huang; Yubo He; Byounggyu Yoo; Jingjing Xie; Samuel John; Ningyan Zhang; Zhiqiang An; Cheng Cheng Zhang
Journal:  Antib Ther       Date:  2021-02-09

Review 4.  Human inhibitory leukocyte Ig-like receptors: from immunotolerance to immunotherapy.

Authors:  Calvin D De Louche; Ali Roghanian
Journal:  JCI Insight       Date:  2022-01-25

Review 5.  Newly Found Peacekeeper: Potential of CD8+ Tregs for Graft-Versus-Host Disease.

Authors:  Weihao Wang; Tao Hong; Xiaoqi Wang; Rui Wang; Yuxuan Du; Qiangguo Gao; Shijie Yang; Xi Zhang
Journal:  Front Immunol       Date:  2021-11-24       Impact factor: 7.561

Review 6.  LILRB4, an immune checkpoint on myeloid cells.

Authors:  Ting Yang; Yixin Qian; Xiaoting Liang; Jianbo Wu; Ming Zou; Mi Deng
Journal:  Blood Sci       Date:  2022-05-17

Review 7.  Insights into mechanisms of graft-versus-host disease through humanised mouse models.

Authors:  Amal Elhage; Chloe Sligar; Debbie Watson; Ronald Sluyter; Peter Cuthbertson
Journal:  Biosci Rep       Date:  2022-09-30       Impact factor: 3.976

8.  Leishmania major infection in humanized mice induces systemic infection and provokes a nonprotective human immune response.

Authors:  Anja Kathrin Wege; Christian Florian; Wolfgang Ernst; Nicole Zimara; Ulrike Schleicher; Frank Hanses; Maximilian Schmid; Uwe Ritter
Journal:  PLoS Negl Trop Dis       Date:  2012-07-24

Review 9.  Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors.

Authors:  Xunlei Kang; Jaehyup Kim; Mi Deng; Samuel John; Heyu Chen; Guojin Wu; Hiep Phan; Cheng Cheng Zhang
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 10.  Molecular and Cellular Characterization of Human CD8 T Suppressor Cells.

Authors:  Zheng Xu; Sophey Ho; Chih-Chao Chang; Qing-Yin Zhang; Elena-Rodica Vasilescu; George Vlad; Nicole Suciu-Foca
Journal:  Front Immunol       Date:  2016-11-30       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.